Skip to main content Skip to navigation
Hamburger Menu
Search icon
Order lookup icon Order lookup icon
Order Lookup
Country Selector Country Selector
United States (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BV421 Mouse Anti-CXCR7
      BV421 Mouse Anti-CXCR7
      Flow cytometric analysis of CXCR7 expression on mouse leukocytes (Left Panel). C57BL/6 splenocytes were treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) and pre-incubated with Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™, Cat. No. 553141 or 553142). To demonstrate the expression of CXCR7 on marginal-zone B lymphocytes, the splenocytes were co-stained with six fluorochrome-conjugated monoclonal antibodies in the BD Horizon™ Brilliant Stain Buffer (Cat. No. 563794/566349/566385): FITC Rat Anti-Mouse CD21/CD35 (Cat. No. 553818 or 561769), Alexa Fluor® 647 Rat Anti-Mouse CD9 (Cat. No. 564233), BD Horizon™ PE-CF594 Rat Anti-Mouse CD45R (Cat. No. 562290 or 562313), BD Horizon™ BUV737 Rat Anti-Mouse CD23 (Cat. No. 564436), BD Horizon™ BUV395 Rat Anti-Mouse IgM (Cat. No. 564025) and either BD Horizon™ BV421 Mouse Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439; dotted-line histograms). The histograms were derived from gated viable splenocytes expressing with the B220-positive, IgM-high, CD21-high, CD23-low, CD9-positive phenotype. Flow cytometric analysis of CXCR7 expression on human CXCR7-transfected 293F cells (Middle and Right Panels). Untransfected 293F cells (Middle Panel) and 293F cells transfected with a human CXCR7 construct (Right Panel) were initially fixed with BD Cytofix Fixation Buffer (Cat. No. 554655) and then stained with either BD Horizon BV421 Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439, dotted-line histogram). The histograms were derived from gated events based on the light scattering characteristics of intact 293F cells. Flow cytometry was performed on a BD LSRFortessa™ X-20 Cell Analyzer.
      BV421 Mouse Anti-CXCR7
      Flow cytometric analysis of CXCR7 expression on mouse leukocytes (Left Panel). C57BL/6 splenocytes were treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) and pre-incubated with Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™, Cat. No. 553141 or 553142). To demonstrate the expression of CXCR7 on marginal-zone B lymphocytes, the splenocytes were co-stained with six fluorochrome-conjugated monoclonal antibodies in the BD Horizon™ Brilliant Stain Buffer (Cat. No. 563794/566349/566385): FITC Rat Anti-Mouse CD21/CD35 (Cat. No. 553818 or 561769), Alexa Fluor® 647 Rat Anti-Mouse CD9 (Cat. No. 564233), BD Horizon™ PE-CF594 Rat Anti-Mouse CD45R (Cat. No. 562290 or 562313), BD Horizon™ BUV737 Rat Anti-Mouse CD23 (Cat. No. 564436), BD Horizon™ BUV395 Rat Anti-Mouse IgM (Cat. No. 564025) and either BD Horizon™ BV421 Mouse Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439; dotted-line histograms). The histograms were derived from gated viable splenocytes expressing with the B220-positive, IgM-high, CD21-high, CD23-low, CD9-positive phenotype. Flow cytometric analysis of CXCR7 expression on human CXCR7-transfected 293F cells (Middle and Right Panels). Untransfected 293F cells (Middle Panel) and 293F cells transfected with a human CXCR7 construct (Right Panel) were initially fixed with BD Cytofix Fixation Buffer (Cat. No. 554655) and then stained with either BD Horizon BV421 Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439, dotted-line histogram). The histograms were derived from gated events based on the light scattering characteristics of intact 293F cells. Flow cytometry was performed on a BD LSRFortessa™ X-20 Cell Analyzer.
      Product Details
      Down Arrow Up Arrow


      BD Horizon™
      ACKR3, CMKOR, RDC1, GPR159
      Mouse (QC Testing), Human (Tested in Development)
      Mouse C57BL/6 IgG2a, κ
      Human CXCR7 Transfected Cell Line
      Flow cytometry (Routinely Tested)
      0.2 mg/ml
      AB_2744473
      Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV421 under optimum conditions, and unconjugated antibody and free BD Horizon BV421 were removed.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant™ dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
      3. An isotype control should be used at the same concentration as the antibody of interest.
      4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      5. Alexa Fluor® is a registered trademark of Molecular Probes, Inc., Eugene, OR.
      6. Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
      7. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      9. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
      10. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      Show More blue down arrow Show Less blue up arrow
      566234 Rev. 2
      Antibody Details
      Down Arrow Up Arrow
      10D1

      The 10D1 monoclonal antibody specifically binds to mouse and human C-X-C chemokine receptor type 7 (CXCR7), a G protein-coupled receptor that interacts with high affinity to SDF-1 (CXCL12) and with low affinity to CXCL11 (I-TAC). These chemokines also bind to CD184 (CXCR4) and CD183 (CXCR3), respectively, and induce functional processes such as calcium mobilization and cell migration. In contrast to CXCR4, CXCR7-dependent signaling outcomes are somewhat unclear and may vary with cell type. CXCR7 is involved in the alignment of marginal-zone B lymphocytes to the splenic marginal zone and also plays critical roles in embryogenesis and malignancies.

      566234 Rev. 2
      Format Details
      Down Arrow Up Arrow
      BV421
      The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV421
      Violet 405 nm
      407 nm
      423 nm
      566234 Rev.2
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "566234" on CiteAb

      Development References (4)

      1. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.. Blood. 2009; 113(24):6085-93. (Biology). View Reference
      2. Mackay CR. Development and Uses for Monoclonal Antibodies to Chemoattractant Receptors. Current Immunology Reviews. 2012; 8Available: http://www.ingentaconnect.com/content/ben/cir/2012/00000008/00000002/art00006 2016, January 16.
      3. Puchert M, Engele J. The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets.. Cell Tissue Res. 2014; 355(2):239-53. (Biology). View Reference
      4. Sierro F, Biben C, Martínez-Muñoz L, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A. 2007; 104(37):14759-14764. (Biology). View Reference
      View All (4) View Less
      566234 Rev. 2

       

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.